Propofol Versus Dexmedetomidine for Sedation of Cancer Patients Undergoing ERCP

NACompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

January 1, 2024

Study Completion Date

February 1, 2024

Conditions
Sedation in ERCP
Interventions
DRUG

Propofol

will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion

DRUG

Dexmedetomidine

will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.

Trial Locations (1)

Unknown

Ahmed Mohamed Soliman, Giza

All Listed Sponsors
lead

National Cancer Institute, Egypt

OTHER

NCT06409104 - Propofol Versus Dexmedetomidine for Sedation of Cancer Patients Undergoing ERCP | Biotech Hunter | Biotech Hunter